The world's first plant-based covid vaccine has been approved.
Key Takeaways:
- The world's first plant-derived Covid-19 vaccine has been approved for use in Canada by Mitsubishi Chemical Holdings Corp and Philip Morris International.
- The vaccine was 71% effective against symptomatic infection in clinical trials and 100% effective against severe disease caused by COVID-19.
A unit of Mitsubishi Chemical Holdings Corp and Philip Morris International have received approval to utilize the world's first plant-derived Covid-19 vaccine in Canada, resulting in a unique vaccination to battle the virus.
Medicago Inc., a biopharmaceutical business established in Quebec City and owned by Mitsubishi Chemical and Philip Morris, and GlaxoSmithKline Plc collaborated on the Covifenz vaccine.
The following are a few things you should know about the Covifenz vaccine:
This is the first COVID-19 vaccine approved by Health Canada, and it's also the first to employ plant-based protein technology.
Covifenz from Medicago is approved as a two-dose schedule of 3.75 micrograms per dosage, given 21 days apart.
The vaccine was 71% effective against symptomatic infection and 100% effective against severe illness caused by COVID-19 in clinical studies.
Data from the Covifenz vaccination reveal that it is effective against various variations, including Delta.
Covifenz demonstrated effectiveness against the Delta and Gamma genotypes in clinical studies, and evidence also suggested efficacy against the Alpha, Lambda, and Mu variants.
Health Canada and the Canadian Public Health Agency will continue to closely monitor the vaccine's safety and take appropriate measures if any safety concerns are discovered.
This is the first COVID-19 vaccine approved by Health Canada, and it's also the first to employ plant-based protein technology.
Side effects that may occur include:
It's usual to experience brief adverse effects after getting vaccinated. These symptoms might continue anywhere from a few hours to many days following immunization.
The body's normal responses are chills, weariness, joint pains, headache, moderate fever, muscle aches, nasal congestion, sore throat, cough, nausea, and diarrhea. It works hard to create a defense against the disease.
Based on data from clinical studies, Health Canada has authorized a dosage regimen of two doses given 21 days apart. 3.75 micrograms of SARS-CoV-2 spike (S) protein and 0.25 milliliters of AS03 adjuvant are included in each dosage.